PL2164520T3 - Cyklodekstryny do podawania kwasów tłuszczowych w tabletkach - Google Patents

Cyklodekstryny do podawania kwasów tłuszczowych w tabletkach

Info

Publication number
PL2164520T3
PL2164520T3 PL08762219T PL08762219T PL2164520T3 PL 2164520 T3 PL2164520 T3 PL 2164520T3 PL 08762219 T PL08762219 T PL 08762219T PL 08762219 T PL08762219 T PL 08762219T PL 2164520 T3 PL2164520 T3 PL 2164520T3
Authority
PL
Poland
Prior art keywords
cyclodextrins
tablets
fatty acids
administering fatty
administering
Prior art date
Application number
PL08762219T
Other languages
English (en)
Inventor
Jo Klaveness
Bjarne Brudeli
Pal Rongved
Original Assignee
Golden Omega Norway As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Golden Omega Norway As filed Critical Golden Omega Norway As
Publication of PL2164520T3 publication Critical patent/PL2164520T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L1/00—Compositions of cellulose, modified cellulose or cellulose derivatives
    • C08L1/02—Cellulose; Modified cellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL08762219T 2007-05-31 2008-06-02 Cyklodekstryny do podawania kwasów tłuszczowych w tabletkach PL2164520T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0710439.1A GB0710439D0 (en) 2007-05-31 2007-05-31 Oral dosage form
PCT/GB2008/001861 WO2008146016A2 (en) 2007-05-31 2008-06-02 Cyclodextrins for administering fatty acids in tablets
EP08762219.7A EP2164520B1 (en) 2007-05-31 2008-06-02 Cyclodextrins for administering fatty acids in tablets

Publications (1)

Publication Number Publication Date
PL2164520T3 true PL2164520T3 (pl) 2020-04-30

Family

ID=38289647

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08762219T PL2164520T3 (pl) 2007-05-31 2008-06-02 Cyklodekstryny do podawania kwasów tłuszczowych w tabletkach

Country Status (7)

Country Link
US (2) US20100291206A1 (pl)
EP (1) EP2164520B1 (pl)
DK (1) DK2164520T3 (pl)
ES (1) ES2758751T3 (pl)
GB (1) GB0710439D0 (pl)
PL (1) PL2164520T3 (pl)
WO (1) WO2008146016A2 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009007084A (es) * 2006-12-27 2009-08-20 Cargill Inc Complejos de inclusion de ciclodextrina y metodos para preparar los mismos.
ITMI20072142A1 (it) * 2007-11-08 2009-05-09 Yervant Zarmanian Composizioni farmaceutiche contenenti statine e derivati di acidi grassi omega-3
GB0817701D0 (en) * 2008-09-26 2008-11-05 Omegatri As Krill oil powder and krill oil tablets
ITFI20080243A1 (it) * 2008-12-15 2010-06-16 Valpharma Sa Formulazioni per la somministrazione orale di acidi grassi omega polienoici in combinazione con statine di origine naturale o semi-sintetica.
US20100272792A1 (en) 2009-04-28 2010-10-28 Avema Pharma Solution, Division of PL Developments Stability additives for dry dha dosage forms
NZ599618A (en) 2009-10-30 2014-08-29 Tharos Ltd Solvent-free process for obtaining phospholipids and neutral enriched krill oils
ES2685291T3 (es) * 2010-12-21 2018-10-08 Omegatri As Antioxidantes en polvo de aceite de pescado y comprimidos
US20150359807A1 (en) * 2014-06-11 2015-12-17 Supernutrition Life-Extension Research, Inc. Dietary Supplement Containing Vitamin A, D3 and Vitamin K2 and Uses Thereof
WO2017158439A1 (en) * 2016-03-16 2017-09-21 Omegatri As Powders and tablets comprising omega-3 fatty acid derivatives and methods for their production
PL3463310T3 (pl) * 2016-05-25 2023-12-04 Evonik Operations Gmbh Tabletki o wysokiej zawartości składników aktywnych soli aminokwasowych kwasów tłuszczowych omega-3
CN108057019A (zh) * 2016-11-09 2018-05-22 西宝生物科技(上海)股份有限公司 一种七烯甲萘醌微胶束、其制备方法、含有该微胶束的口服制剂及其应用
CN106511276A (zh) * 2016-12-13 2017-03-22 云南师范大学 水溶性的促凝血药维生素k2固态复合物及其制备方法
CN118715017A (zh) * 2022-02-18 2024-09-27 贝伦治疗公益公司 用2-羟基丙基-β-环糊精治疗高甘油三酯血症

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5813541A (ja) * 1981-07-16 1983-01-26 Kureha Chem Ind Co Ltd エイコサペンタエン酸又はドコサヘキサエン酸のシクロデキストリン包接化合物
CA1218376A (en) * 1983-05-28 1987-02-24 Sekimoto, Hiroshi Compositions containing unsaturated fatty acid compounds and method of stabilizing unsaturated fatty acid compounds
JPS6034156A (ja) * 1983-08-08 1985-02-21 Hayashibara Biochem Lab Inc エイコサペンタエン酸包接化合物及びこれを含有した飲食物
US4725427A (en) * 1984-03-13 1988-02-16 Albion International, Inc. Effervescent vitamin-mineral granule preparation
JPS61200942A (ja) * 1985-03-04 1986-09-05 Nisshin Flour Milling Co Ltd ビタミンK↓2−ジメチル−β−シクロデキストリン包接化合物
JPH01218573A (ja) * 1988-02-25 1989-08-31 Yoshio Tanaka ドナリエラ藻体含有固形状食品の製造法
IT1243192B (it) * 1990-08-09 1994-05-24 Staroil Ltd Complessi di acidi grassi polinsaturi a lunga catena e di loro derivati, con ciclodestrine
AU673700B2 (en) * 1993-01-27 1996-11-21 Scotia Holdings Plc Triglycerides
DE69425948T2 (de) * 1993-12-06 2001-02-22 Takeda Chemical Industries, Ltd. Zusammensetzung mit verbesserter Wasserlöslichkeit, enthaltend eine Wasserunlösliche oder an Wasser schwerunlösliche Verbindung
IT1274734B (it) * 1994-08-25 1997-07-24 Prospa Bv Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
US5843919A (en) * 1996-11-25 1998-12-01 Burger; John A. Composition and method for the treatment of arthritis
AU719076B2 (en) * 1996-12-19 2000-05-04 Daiichi Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration
KR100267576B1 (ko) * 1998-07-25 2000-11-01 허계성 활성성분을 분리함유한 츄잉 연질정제 및 그의 제조방법
FR2790758A1 (fr) * 1999-03-09 2000-09-15 Commissariat Energie Atomique Solubilisation d'acides gras polyinsatures et de leurs derives par formation de complexes d'inclusion avec une cyclodextrine et leur utilisation dans des compositions pharmaceutiques, cosmetiques ou alimentaires
CN1113657C (zh) * 2000-07-12 2003-07-09 刘玉 高浓鱼油缓释片剂及其制法
GB0212749D0 (en) * 2002-06-01 2002-07-10 Boots Co Plc Personal care compositions
GB0220182D0 (en) * 2002-08-30 2002-10-09 Cardiovascular Res Inst Maastr Organic compounds
CN100584385C (zh) * 2003-07-10 2010-01-27 协和发酵生化株式会社 片剂及其制备方法
EP1858352B1 (en) * 2005-02-18 2013-06-05 Delante Health AS A composition comprising a powder containing microencapsulated polyunsaturated long-chain esterified fatty acids distributed in an effervescent base
JP2006249050A (ja) * 2005-03-14 2006-09-21 Cyclochem:Kk 安定化された複合体及びその製造方法
US20070104779A1 (en) * 2005-11-07 2007-05-10 Rongen Roelof M Treatment with omega-3 fatty acids and products thereof
FR2898817B1 (fr) * 2006-03-23 2008-08-08 Univ Rouen Association de substance oleagineuse avec un melange d'au moins deux cyclodextrines
MX2009007084A (es) * 2006-12-27 2009-08-20 Cargill Inc Complejos de inclusion de ciclodextrina y metodos para preparar los mismos.

Also Published As

Publication number Publication date
US20110275594A1 (en) 2011-11-10
ES2758751T3 (es) 2020-05-06
GB0710439D0 (en) 2007-07-11
WO2008146016A3 (en) 2009-07-16
WO2008146016A2 (en) 2008-12-04
EP2164520A2 (en) 2010-03-24
DK2164520T3 (da) 2019-11-25
EP2164520B1 (en) 2019-10-30
US20100291206A1 (en) 2010-11-18

Similar Documents

Publication Publication Date Title
HUS1800043I1 (hu) 514 számú gyógyszerkészítmény
ZA201304728B (en) Boronate ester conpoundds and pharmaceutical compositions thereof
IL213341A0 (en) Dipeptide linked medicinal agents
ZA201104036B (en) Fatty acids for use as a medicament
ZA201100615B (en) Appetising medicament for oral administration in solid form
DK2164520T3 (da) Cyclodextriner til indgivelse af fedtsyrer i tabletter
GB0617191D0 (en) Improvements in pharmaceutical compositions
HUE037396T2 (hu) Cisz egyszeresen telítetlen zsírsavak alfa-származékai gyógyszerekként való alkalmazásra
EP2268278A4 (en) PHARMACEUTICAL COMPOSITION
ZA201006766B (en) Pharmaceutical composition 271
IL207734A0 (en) Pharmaceutical composition
GB2464200B (en) Pharmaceutical composition
GB0817969D0 (en) Pharmaceutical composition
AU325326S (en) Dinosaur 2 in 1 single bed
SI2271321T1 (sl) Farmacevtski sestavek 271
GB0810661D0 (en) Toilet in bed
GB0618348D0 (en) Dietary solution containing essential fatty acids
GB0813031D0 (en) Pharmaceutical formulations
GB0810217D0 (en) Pharmaceutical formulations
GB0614848D0 (en) Improvements in pharmaceutical compositions
GB0813734D0 (en) Com-fee 2 in 1
GB0813185D0 (en) Improvements in actibacterial drugs
GB0817974D0 (en) Pharmaceutical composition
GB0817566D0 (en) Pharmaceutical composition